Lipitor Market analysis and forecasts Report 2007-2012 2017 2023

In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.

However, as Lipitor’s blockbuster revenue is seriously threatened by imminent patent expiration in some of the drug’s largest markets such as the US, Japan and the UK, there is significant unrest between Pfizer’s key stakeholders about the future of the drug. Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1 billion annual drug sales or more, as well as the fast expanding generic market in which India’s Ranbaxy is a dominant force.

What questions does the report answer?

• Has the success of Pfizer’s Lipitor been overstated?

• Did Pfizer create a monster in Lipitor?

• Have Lipitor sales redefined the bounds that pharmaceutical margins can now reach?

• How imminent is Lipitor patent expiration?

• Which key markets will suffer the consequence of Lipitor expiry?

• Is Ranbaxy ready for generic Lipitor?

• Do the fast developing markets, CEE and the Latin America segment hold the key to future sales after Lipitor’s patent expiration?

• Is Lipitor a victim of the struggling Blockbuster Model?

• What is next for Lipitor?

• Do the fast developing markets, CEE and Latin America segment hold the key to future sales after Lipitor’s patent expiration?

• Is Lipitor, a victim of the struggling Blockbuster Model?

• What is next for Lipitor?

As Pfizer’s Lipitor struggles to fend off the immediate entry of Ranbaxy’s generic Lipitor, in key markets, the legal challenges surrounding the number one drug have set a new benchmark for pharmaceutical companies protecting branded products. Industry observers including Visiongain predicts that Pfizer’s crises are far from over, as the high revenue streams of Lipitor will experience significant challenges before the commencement of the next decade.

Moreover, Pfizer’s lack of success to replace Lipitor with Torcetrapib has escalated the company’s near-term battles besides the ever-tighter regulatory hurdles, reduced R&D efficiency and increased competition, creating formidable therapeutic challenges as healthcare payers influence pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, the rising incidence of multiple diseases, ageing populations, the rising living standards and fast-developing geographical markets. The future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period of economic changes and pressures.

This report includes detailed five-year forecasts over the period 2008-2013, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

This unique in-depth management report examines the future prospects for Lipitor from 2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven major markets (7MM). This detailed report highlights the most compelling must know issues- Lipitor’s patent contention by Pfizer in both 7MM and other markets in order to block Ranbaxy’s immediate penetration of generic Lipitor. In light of healthcare drug bills increasing exponentially, generic Lipitor will be welcomed by managed care organisations (MCO) and further widen the generic revenue margins, visiongain concludes. This report also tackles Lipitor’s significant developments, potential opportunities on the market and important contemporary matters, especially commercial drivers and restraints.

Unique benefits to you when you order this report:

- Primary research throughout: you will not find this information anywhere else

- Full searchable report when you buy the company or corporate editions

- Easily downloadable copies of the report available for offline reading

- The report is filled with detailed charts, analysis, figures, graphs and tables

- PRICING -

- Single use licence $2995.00

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00

May 2008
Table of Contents

Price
Single Use Licence $2995.00
Department Licence 5 Users $5,995.00
Company-wide Intranet Licence $9,995.00
Company over 2500 employees $13,995.00